GlassScriptPhysician profile
Steven J Edginton
NPI 1598064842
$3,695.25
in general payments reported to CMS, 2019-2025
38 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $970 · 2022: $850 · 2023: $778 · 2024: $664 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.21 | 2021-2025 | |
| Novo Nordisk INC | $416.67 | 2021-2025 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $392.10 | 2021-2025 | Nexletol |
| Amgen INC. | $271.15 | 2021-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $264.78 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.36 | 2021-2025 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $247.74 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $145.48 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $133.55 | 2021-2025 | Airsupra, Fasenra |
| Seqirus USA INC | $76.05 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Inspire Medical Systems, INC. | $62.47 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $61.52 | 2022 | |
| Merck Sharp & Dohme LLC | $49.59 | 2022-2023 | Vaxelis, Gardasil 9, Pneumovax 23 |
| Glaxosmithkline, LLC. | $47.63 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Edginton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.